Minakem Generic APIs Minakem Generic APIs

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"eFFECTOR\u2019s Tomivosertib Shows Positive Phase 2 Results in Non-Small Cell Lung Cancer in Combination with Checkpoint Inhibitors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Locust Walk","pharmaFlowCategory":"D","amount":"$235.0 million","upfrontCash":"Undisclosed","newsHeadline":"eFFECTOR Therapeutics and Locust Walk Acquisition Corp. Announce Merger Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"eFFECTOR Therapeutics Doses First Patient in Phase 2b KICKSTART Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"eFFECTOR Therapeutics Announces Transition in Clinical Leadership","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Northwestern University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"eFFECTOR Therapeutics to Collaborate with the Northwestern University Division of Hematology and Oncology on an Investigator-Initiated Phase 1 Dose Escalation Trial Evaluating Tomivosertib in Patients with Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"eFFECTOR Therapeutics Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"eFFECTOR Therapeutics Announces Closing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals for Tomivosertib

    Menu

    Tomivosertib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Effector Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer

              Details:

              eFT508 (tomivosertib) is a potent and highly selective MNK inhibitor, small molecule drug candidate, which is being evaluated in combination with pembrolizumab for the treatment of non-small cell lung cancer.

              Lead Product(s): Tomivosertib,Pembrolizumab

              Therapeutic Area: Oncology Product Name: eFT508

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 04, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Effector Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              eFFECTOR Therapeutics Announces Closing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

              Details:

              The net proceeds will focus on the development of eFT508 (tomivosertib), which is a small molecule inhibitor of MNK used for the treatment of patients with metastatic non-small cell lung cancer (NSCLC).

              Lead Product(s): Tomivosertib,Pembrolizumab

              Therapeutic Area: Oncology Product Name: eFT508

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: H.C. Wainwright & Co.

              Deal Size: $15.0 million Upfront Cash: Undisclosed

              Deal Type: Public Offering January 29, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Effector Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              eFFECTOR Therapeutics Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

              Details:

              The net proceeds will be used to advance company's pipeline including, eFT508 (tomivosertib), an oral small molecule inhibitor of MNK1 and MNK2 and currently in Phase II for Head And Neck Cancer.

              Lead Product(s): Tomivosertib,Pembrolizumab

              Therapeutic Area: Oncology Product Name: eFT508

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: H.C. Wainwright & Co.

              Deal Size: $15.0 million Upfront Cash: Undisclosed

              Deal Type: Public Offering January 25, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Effector Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              eFFECTOR Therapeutics to Collaborate with the Northwestern University Division of Hematology and Oncology on an Investigator-Initiated Phase 1 Dose Escalation Trial Evaluat...

              Details:

              The collaboration aims to evaluate eFT508 (tomivosertib), an inhibitor of mitogen-activator protein kinase interacting kinase (MNK) 1 and 2 and blocks phosphorylation of eukaryotic initiation factor 4E, in patients with relapsed/refractory Acute Myeloid Leukemia.

              Lead Product(s): Tomivosertib

              Therapeutic Area: Oncology Product Name: eFT508

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Northwestern University

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration October 24, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Effector Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              eFFECTOR Therapeutics Announces Transition in Clinical Leadership

              Details:

              eFT505 (tomivosertib), a potent and highly selective inhibitor of the immunosuppressive kinases MNK-1 and 2, blocks the expression of checkpoint proteins PD-1, PD-L1, and LAG-3 as well as immunosuppressive cytokines IL-6 and IL-8.

              Lead Product(s): Tomivosertib,Pembrolizumab,Pemetrexed

              Therapeutic Area: Oncology Product Name: eFT505

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 04, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Effector Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              eFFECTOR Therapeutics Doses First Patient in Phase 2b KICKSTART Clinical Trial

              Details:

              Cohort two will assess the safety and efficacy of tomivosertib in combination with pembrolizumab at treatment initiation in the frontline setting. Both cohorts in the trial will have a control arm with placebo in combination with pembrolizumab.

              Lead Product(s): Tomivosertib,Pembrolizumab

              Therapeutic Area: Oncology Product Name: eFT508

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 09, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Effector Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              eFFECTOR Therapeutics and Locust Walk Acquisition Corp. Announce Merger Agreement

              Details:

              Transaction includes up to $175 m in trust at LWAC and a concurrent, fully committed $60 m PIPE offering. The funds will be used to Push eFFECTOR’s pipeline through multiple clinical milestones including expansion of tomivosertib and zotatifin into additional indications.

              Lead Product(s): Tomivosertib,Pembrolizumab

              Therapeutic Area: Oncology Product Name: eFT508

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Locust Walk

              Deal Size: $235.0 million Upfront Cash: Undisclosed

              Deal Type: Merger May 27, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Effector Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              eFFECTOR’s Tomivosertib Shows Positive Phase 2 Results in Non-Small Cell Lung Cancer in Combination with Checkpoint Inhibitors

              Details:

              In a Phase 2 study, open-label study, tomivosertib demonstrated antitumor activity in combination with checkpoint inhibitors (CPI) in patients with solid tumors who progressed on CPI treatment.

              Lead Product(s): Tomivosertib,Anti PD1/PD-L1 therapy

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 29, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Symbiotec: Global API manufacturer, specializing in Cortico-Steroids & Steroid-Hormone APIs.
              Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
              Post Enquiry
              POST ENQUIRY